Sunshine Biopharma (SBFM) Net Income towards Common Stockholders (2011 - 2026)

Sunshine Biopharma (SBFM) has 14 years of Net Income towards Common Stockholders data on file, last reported at -$1.2 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 5.43% year-over-year to -$1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.0 million (up 4.35% YoY) and the FY2025 annual result came in at -$6.0 million, down 16.39% from the prior year.
• Net Income towards Common Stockholders grew to -$1.2 million in Q1 2026, from -$2.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $295951.0 in Q3 2025 to a low of -$23.5 million in Q4 2022.
• A 5-year average of -$2.6 million and a median of -$1.2 million in 2026 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders tumbled 3624.47% — and 2025, when it jumped 124.71%.
• Tracing SBFM's Net Income towards Common Stockholders over 5 years: stood at -$23.5 million in 2022, then jumped by 94.85% to -$1.2 million in 2023, then plunged by 78.07% to -$2.2 million in 2024, then advanced by 0.8% to -$2.1 million in 2025, then jumped by 41.9% to -$1.2 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$1.2 million (Q1 2026), -$2.1 million (Q4 2025), and $295951.0 (Q3 2025), per Business Quant data.